JP2022504036A5 - - Google Patents

Info

Publication number
JP2022504036A5
JP2022504036A5 JP2021517954A JP2021517954A JP2022504036A5 JP 2022504036 A5 JP2022504036 A5 JP 2022504036A5 JP 2021517954 A JP2021517954 A JP 2021517954A JP 2021517954 A JP2021517954 A JP 2021517954A JP 2022504036 A5 JP2022504036 A5 JP 2022504036A5
Authority
JP
Japan
Prior art keywords
reuptake inhibitors
agent
antidepressant
serotonin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504036A (ja
Filing date
Publication date
Priority claimed from PCT/IB2018/059107 external-priority patent/WO2020070547A1/en
Application filed filed Critical
Priority claimed from PCT/IB2019/058476 external-priority patent/WO2020070706A1/en
Publication of JP2022504036A publication Critical patent/JP2022504036A/ja
Publication of JP2022504036A5 publication Critical patent/JP2022504036A5/ja
Priority to JP2024078458A priority Critical patent/JP2024105527A/ja
Pending legal-status Critical Current

Links

JP2021517954A 2018-10-05 2019-10-04 大うつ病性障害を治療するためのエスケタミンの投与計画 Pending JP2022504036A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078458A JP2024105527A (ja) 2018-10-05 2024-05-14 大うつ病性障害を治療するためのエスケタミンの投与計画

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862741562P 2018-10-05 2018-10-05
US62/741,562 2018-10-05
PCT/IB2018/059107 WO2020070547A1 (en) 2018-10-05 2018-11-19 Dosage regime of esketamine for treating major depressive disorder
IBPCT/IB2018/059107 2018-11-19
US201962867354P 2019-06-27 2019-06-27
US62/867,354 2019-06-27
PCT/IB2019/058476 WO2020070706A1 (en) 2018-10-05 2019-10-04 Dosage regime of esketamine for treating major depressive disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078458A Division JP2024105527A (ja) 2018-10-05 2024-05-14 大うつ病性障害を治療するためのエスケタミンの投与計画

Publications (2)

Publication Number Publication Date
JP2022504036A JP2022504036A (ja) 2022-01-13
JP2022504036A5 true JP2022504036A5 (cg-RX-API-DMAC7.html) 2023-11-10

Family

ID=70551470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517954A Pending JP2022504036A (ja) 2018-10-05 2019-10-04 大うつ病性障害を治療するためのエスケタミンの投与計画
JP2024078458A Pending JP2024105527A (ja) 2018-10-05 2024-05-14 大うつ病性障害を治療するためのエスケタミンの投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078458A Pending JP2024105527A (ja) 2018-10-05 2024-05-14 大うつ病性障害を治療するためのエスケタミンの投与計画

Country Status (9)

Country Link
US (9) US11865088B2 (cg-RX-API-DMAC7.html)
EP (1) EP3860579A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022504036A (cg-RX-API-DMAC7.html)
KR (1) KR20210074275A (cg-RX-API-DMAC7.html)
CN (1) CN112702995A (cg-RX-API-DMAC7.html)
AU (1) AU2019352028A1 (cg-RX-API-DMAC7.html)
CA (1) CA3113198A1 (cg-RX-API-DMAC7.html)
IL (1) IL280845A (cg-RX-API-DMAC7.html)
WO (1) WO2020070706A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
US20240197652A1 (en) 2021-05-25 2024-06-20 Awakn Ls Europe Holdings Limited Ketamine in the treatment of behavioral addictions
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
CN105534936B (zh) 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
WO2009137843A2 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
KR20220044380A (ko) 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
WO2015066172A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3272338B1 (en) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Oral dosage form of ketamine
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
KR102604397B1 (ko) 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) * 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
WO2018079693A1 (ja) 2016-10-27 2018-05-03 国立大学法人 千葉大学 (s)-ノルケタミンおよびその塩の医薬品としての応用
WO2018102488A1 (en) 2016-11-30 2018-06-07 Wolfson Philip E Ketamine for the treatment of menstrually related symptoms
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3923920A4 (en) 2019-08-05 2022-11-23 The Ketamine Research Foundation KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Similar Documents

Publication Publication Date Title
US11786491B2 (en) Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
JP2015516395A5 (cg-RX-API-DMAC7.html)
JP2011523949A5 (cg-RX-API-DMAC7.html)
JP2023100904A5 (cg-RX-API-DMAC7.html)
JP5827239B2 (ja) フマギロール型化合物並びにその製造方法及び使用方法
RU2016143091A (ru) Органические соединения
JP6479670B2 (ja) 7,8−ジヒドロキシフラボンおよび7,8−置換フラボン誘導体、組成物、およびそれらに関連する方法
HRP20110206T1 (hr) Derivati 3-(heteroaril-oksi)-2-alkil-1-aza-bicikloalkila kao alfa.7-nachr liganda za liječenje cns bolesti
JP2017509686A5 (cg-RX-API-DMAC7.html)
RU2020123764A (ru) Органические соединения
RU2018137496A (ru) Органические соединения
JP2021511365A5 (cg-RX-API-DMAC7.html)
JP2002516282A (ja) 難治性鬱病の処置のための組合せ治療
MXPA06002619A (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion.
EP2509589B1 (fr) Compositions antivirales pharmaceutiques ou vétérinaires comprenant la midodrine ou la desglymidodrine
JP2023507926A5 (cg-RX-API-DMAC7.html)
JP2022506113A5 (cg-RX-API-DMAC7.html)
JP2007513052A5 (cg-RX-API-DMAC7.html)
JP2013032308A5 (cg-RX-API-DMAC7.html)
JP2016520112A5 (cg-RX-API-DMAC7.html)
TWI455712B (zh) 增強神經藥方療效的山梨酸與苯甲酸及其衍生物
JP2009542820A5 (cg-RX-API-DMAC7.html)
WO2012083034A1 (en) Modulation of neurotrophic factors by omega-3 fatty acid formulations
JP2024541315A5 (cg-RX-API-DMAC7.html)
JP2024538015A5 (cg-RX-API-DMAC7.html)